As Biogen heads towards important depression data, Sanofi looks to oncology for growth.
The most important of this year’s two virtual AACRs features immunotherapy combos, new Kras players and first clinical data for several assets.
The group hopes for a better result with a higher dose of its antisense projects, but it also has a back-up plan.
Full data on Lilly's Alzheimer’s antibody will disappoint some, and point to a long road ahead.
Expectations are high ahead of a detailed look at donanemab data, but hopes for a fast path to market feel overblown.
As several big pharma companies drop Parkinson’s projects, attention turns to gene therapies and repurposing diabetes drugs.
March will see big US decisions for Evrenzo and ide-cel, while tanezumab goes in front of an advisory committee.
The relatively low-key asset might at least partly be responsible for Biocryst shares more than doubling since the start of December.
Merck & Co/Eisai’s Clear study results look better than Bristol/Exelixis’s Checkmate-9ER, but the big loser could be Pfizer.